Application of formononetin in preparing medicine for preventing and treating airway inflammation and asthma

A technology for formononetin and respiratory tract, which is applied to the application field of formononetin in the preparation of drugs for preventing and treating respiratory tract inflammation and asthma

Inactive Publication Date: 2012-07-11
NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
View PDF5 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are still few reports on the pharmacological action and mechanism of the compound's effect site and effect components on respiratory diseases, which is far from the actual needs of the majority of patients. Especially, it is worth digging deeper to find effective substances in traditional Chinese medicine and effective prescriptions.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of formononetin in preparing medicine for preventing and treating airway inflammation and asthma
  • Application of formononetin in preparing medicine for preventing and treating airway inflammation and asthma
  • Application of formononetin in preparing medicine for preventing and treating airway inflammation and asthma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Improvement effect of embodiment 1 on experimental mouse lung pathology

[0027] Balb / C mice were randomly divided into 7 groups, 12 in each group: (1) blank control group; (2) model group; (3) dexamethasone (DM) group; (4) rosiglitazone group; ( 5) Formononetin high dose group; (6) Formononetin medium dose group; (7) Formononetin low dose group. Each group received subcutaneous injection of 0.1 mL of sensitization solution (0.2 ml of sensitization solution containing 0.1 mg of OVA and 0.02 mg of aluminum hydroxide) on day 1, intraperitoneal injection of 0.1 mL of sensitization solution per mouse, and subcutaneous injection of sensitization solution on day 8. 0.1mL / mouse, and 0.1mL / mouse intraperitoneal injection of sensitization solution. On the 14th to 27th day, the mice were placed in a transparent airtight container and challenged with 20mL nebulized inhalation (5% OVA), 20min each time, 1 times / day. After the 21st day, the formononetin low-dose group (0.01g·Kg -...

Embodiment 2

[0030] Effect of Example 2 on the level of inflammatory cells in mouse blood and tracheal lavage fluid

[0031] Balb / C mice were randomly divided into 7 groups, 12 in each group: (1) blank control group; (2) model group; (3) dexamethasone control group; (4) rosiglitazone control group; (5) Formononetin high dose group; (6) Formononetin medium dose group; (7) Formononetin low dose group. Each group received a subcutaneous injection of 0.1 mL of the sensitizing solution per mouse on the first day, an intraperitoneal injection of 0.1 mL per mouse, a subcutaneous injection of 0.1 mL of the sensitizing solution on the eighth day, and an intraperitoneal injection of 0.1 mL per mouse. On the 14th to 27th day, the mice were placed in a transparent airtight container and challenged by aerosol inhalation of 20 mL of nebulized solution, 20 min each time, once a day. After the 21st day, the formononetin low-dose group (0.01g·Kg -1 d - 1 ), formononetin middle dose group (0.02g·Kg -1 ...

Embodiment 3

[0037] Effect of Example 3 on the levels of inflammatory cytokines in airway lavage fluid

[0038] (1) The mice in the model and each medication group were taken, tracheotomy and intubation, alveolar lavage with 0.5mL PBS, repeated 3 times, and centrifuged at 1200r / min for 5min. The supernatant of the lavage fluid was stored in a -70°C refrigerator until testing. The levels of cytokines such as IL-4 and IL-7 were detected by ELISA method. The results showed that different doses of formononetin groups could reduce the contents of IL-17 and IL-4 in the airway lavage fluid, which was statistically significant compared with the model group (P image 3 shown.

[0039] (2) SP method was used for immunohistochemistry. Five high-power fields of view were taken from each slice of lung tissue, and the optical density values ​​of each group were measured with Image Pro Plus 5.0.2 image analysis software. The results see that formononetin reduces the expression of IL-17 in lung tissue, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a novel application of formononetin in the medical science, in particular to the application of formononetin in preparing medicine for preventing and treating airway inflammation and asthma. Pharmacological test result shows that the formononetin participates in reducing the allergic airway inflammation of model animals/occurring and developing of asthma lesion; reducing the of damage inflammatory factor to the human bronchial epithelial cell in vitro and the formononetin can be used for preparing the medicine for treating airway inflammation diseases, such as asthma, bronchitis, capillary bronchitis and air or non-air idiotoxin or inflammatory or non-inflammatory of irritant; and specifically, the formononetin has the application in preparing medicine for treating allergic airway inflammation and asthma disease.

Description

technical field [0001] The present invention relates to the new application of formononetin in medicine, in particular to the application of formononetin in the preparation of medicines for the treatment and prevention of respiratory inflammation and asthma, especially for the treatment of airway allergic inflammation and asthma Uses in medicine. Background technique [0002] Respiratory diseases are common clinical diseases, which can occur in all age groups and have various clinical manifestations. Among them, allergic airway inflammation, asthma and other diseases pose a threat to human health and even life, so they have attracted extensive attention. [0003] At present, many drugs for airway inflammation and asthma have limited clinical application due to long-term use and side effects, such as clinical use of hormone therapy to prevent and control bronchial asthma, but in addition to side effects, the dosage regimen is also relatively complicated. It is suggested that...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P11/00A61P11/06A61P29/00
Inventor 范欣生俞晶华唐于平高璐段金廒
Owner NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap